全球人工細胞療法技術進步市場，2025-2029年

Technological Advances in Engineered Cell Therapies, Global, 2025-2029

出版日期: 2025年09月02日 | 出版商:

Frost & Sullivan | 英文 33 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

人工細胞治療的新趨勢與技術

基因工程細胞療法已成為一個突破性的醫學領域，超越了全身性藥物治療和主流免疫抑制療法等傳統療法，為複雜疾病提供持久、可程式設計、標靶治療。本文探討了基因工程細胞療法的最新技術進展，展示了包括基因編輯、合成生物學和體內編程在內的細胞工程技術的快速發展如何推動了下一代細胞療法的開發，使其具有前所未有的精準度和多功能性。美國FDA核准用於治療滑膜肉瘤的afamitresgene autoleucel（Tecelra）檢驗固態腫瘤治療的一個轉折點，而T細胞工程仍然處於前沿。諸如與查核點抑制劑和溶瘤病毒的整合、雙靶向CAR-T細胞和裝甲CAR-T細胞等新方法提高療效和持久性。邏輯閘、終止開關和SynNotch受體等合成生物學技術的發展進一步實現了模組化、特異性疾病的治療反應。透過封閉式自動化和人工智慧驅動的品管，Cellarless、Ori Biotech 和 Serino 努力確保生產的可擴展性和一致性。透過將工程細胞療法與細胞激素和小分子結合，腫瘤學、自體免疫疾病、感染疾病和纖維化疾病的治療潛力增加。值得注意的是，Sana Biotechnology 用於治療糖尿病的免疫降低 iPSC 和 Cartesian Therapeutics 用於治療重症肌無力的RNA 修飾細胞療法等努力表現出超越腫瘤學的動力。臨床試驗結果突顯了 CAR-T 平台的主導地位，特別是在針對骨髓惡性腫瘤的早期研究中，但固態腫瘤、自體免疫疾病（例如多發性硬化症和狼瘡）和感染疾病（例如 HIV 和肝炎）也越來越受歡迎。現成的和同種異體療法的廣泛可用性為提高可及性和降低成本提供了巨大的希望。策略聯盟、新的相關人員、賦能技術以及區域成長動力塑造工程細胞療法的未來，本研究將對所有這些因素檢驗。隨著工程細胞療法在慢性疾病領域的應用以及向擴充性平台和應用的轉變，該領域的治療和商業性影響力預計將顯著成長。

Engineered cell therapies have become a revolutionary medical field, surpassing conventional methods such as systemic medications and prominent immunosuppression to provide long-lasting, programmable, and targeted treatments for complicated diseases. Recent technical developments in engineered cell therapies examine how the rapid growth of cell engineering technologies, including gene editing, synthetic biology, and in vivo programming, has made it possible to develop next-generation cell therapies with formerly unattainable accuracy and versatility. The US FDA's approval of afamitresgene autoleucel (Tecelra) for synovial sarcoma represents a turning point for solid tumor therapies, and T-cell engineering is still at the forefront. Both efficacy and durability are being improved by novel approaches such as integration with checkpoint inhibitors or oncolytic viruses, as well as dual-targeted and armored CAR-T cells. Modular, disease-specific therapeutic responses are further made possible by developments in synthetic biology, such as logic gates, kill switches, and SynNotch receptors. Through closed-loop automation and AI-powered quality control, Cellares, Ori Biotech, and Cellino are addressing manufacturing scalability and consistency. Therapeutic potential in oncology, autoimmune, infectious, and fibrotic diseases is being increased by combining engineered cell therapies with cytokines and small molecules. Notably, initiatives such as Sana Biotechnology's hypoimmune iPSCs for diabetes and Cartesian Therapeutics' RNA-modified cell therapy for myasthenia gravis demonstrate growing momentum beyond oncology. Clinical trial results highlight the predominance of CAR-T platforms in early-stage research, particularly for hematologic malignancies, whereas solid tumors, autoimmune diseases (multiple sclerosis and lupus, for example), and infectious diseases (such as HIV and hepatitis) are gaining popularity. There are significant prospects for increased accessibility and lower costs due to the popularity of off-the-shelf and allogeneic therapies. The future of engineered cell therapies is being shaped by strategic alliances, emerging stakeholders, enabling technologies, and regional growth dynamics, all of which this study examines. The field's therapeutic and commercial impact is expected to significantly increase as it shifts to applications for chronic diseases and scalable platforms and applications.

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8
The Impact of the Top 3 Strategic Imperatives on the Engineered Cell Therapy Industry
Growth Opportunities Fuel the Growth Pipeline Engine
Research Methodology

Growth Opportunity Analysis

Scope of Analysis
Segmentation: Snapshot of Engineered Cell Therapies

Growth Generator

Growth Drivers
Growth Restraints

Trends in Engineered Cell Therapeutics

Need for Advanced Cell Therapeutics
Trends in Advanced Engineered Cell Therapeutics
Therapeutic Development Trends in Engineered Cell Therapies

Cell Therapies: Clinical Trial Analysis

Cell Therapy Types: Snapshot
Clinical Development Landscape of Engineered Cell Therapies
Therapeutic Indications Driving Cell Therapy Development
Leading Companies in Clinical Development for Engineered Cell Therapies
Advanced CAR-T Platforms for Broader Indications

Engineered Cell Therapies: Current Landscape

Stakeholders Developing Emerging Next-Generation Cell Therapies
Engineered Cell Therapies-Beyond Oncology
Current Gaps and Potential Opportunities for Cell Therapies
Accelerating Access and Delivery of Engineered Cell Therapies
Enabling Technologies and Platforms for Advanced Engineered Cell Therapies

Funding and Collaboration Landscape

Key Collaborations in Engineered Cell Therapies, Global, 2023-2025
Engineered Cell Therapy Deals and Investment Trends
Snapshot of Industry Funding Global, 2023-2025
Snapshot of Academia Funding Global, 2023-2025
Regional Trends in Cell Therapy Development and Adoption

Growth Opportunity Universe in Engineered Cell Therapies

Growth Opportunity 1: AI and ML Integration in Advancing Cell Therapies
Growth Opportunity 2: Next-Generation Off-the-Shelf Allogeneic Cell Therapies
Growth Opportunity 3: Manufacturing Innovation and Decentralization for Advancing Cell Therapy